Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD

(4523)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 655 B
EBIT 2020 -
Net income 2020 66 838 M
Finance 2020 150 B
Yield 2020 2,38%
Sales 2021 676 B
EBIT 2021 -
Net income 2021 70 163 M
Finance 2021 206 B
Yield 2021 2,44%
P/E ratio 2020 26,71
P/E ratio 2021 25,90
EV / Sales2020 2,63x
EV / Sales2021 2,47x
Capitalization 1 873 B
More Financials
Company
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (92.2%): prescribed drugs, health products, etc.; - other (7.8%): food additives, chemical products, etc. Net sales are... 
Sector
Pharmaceuticals
Calendar
06/19 | 09:00pmShareholder meeting
More about the company
Surperformance© ratings of Eisai Co., Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on EISAI CO., LTD
01:36aEISAI : Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug..
AQ
01:34aEISAI : to Present Latest Data on Perampanel at 33rd International Epilepsy Cong..
AQ
06/14EISAI : to Present FYCOMPA Seizure FREEDOM Data in New Onset Patients and Pediat..
AQ
06/12EISAI : Extensive Analyses of Phase 3 Data for Investigational Lemborexant Asses..
AQ
06/12EISAI : Lemborexant Respiratory Safety Data Presented at SLEEP 2019
AQ
06/05EISAI : Announces Additional Data from Ongoing Phase 1 Trial of Investigational ..
AQ
05/30EISAI : Adriana Herrera Appointed Senior Vice President, Americas Commercial Onc..
AQ
05/29EISAI : to Present Eight Lemborexant Posters at SLEEP 2019 Meeting, Including Ne..
AQ
05/29EISAI : To present latest data on lemborexant including integrated analysis of p..
AQ
05/21EISAI : Announces the Appointment of Dr. Luca Dezzani as Vice President, U.S. Me..
AQ
More news
Analyst Recommendations on EISAI CO., LTD
More recommendations
Sector news : Pharmaceuticals - NEC
03:39aMiners, Ashtead support UK shares; AstraZeneca gains
RE
03:29aBAYER : Roche wins Japan approval for personalised cancer drug Rozlytrek
RE
03:09aASTRAZENECA : Lynparza gets EU nod as first-line ovarian cancer maintenance trea..
RE
02:48aPFIZER : Expands Cancer-Treatment Lineup
DJ
01:30aSanofi, Google to Develop Healthcare Innovation Lab
DJ
More sector news : Pharmaceuticals - NEC
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 6 847  JPY
Spread / Average Target 8,4%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD-24.49%17 422
JOHNSON & JOHNSON8.55%348 981
PFIZER-2.04%233 072
ROCHE HOLDING LTD.13.11%227 848
NOVARTIS20.71%220 893
MERCK AND COMPANY9.02%206 641